Evidence map›Paper›PMID 37887344›Full record

ArticleCells2023

Oocyte-Specific Deletion of

Allison K Tscherner, Taylor McClatchie, Gracia Kaboba, Detlev Boison, Jay M Baltz

Open access · goldAbstract read
In one paragraph

Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Allison K TschernerOttawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada.
Taylor McClatchieOttawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada.
Gracia KabobaOttawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada.
Detlev BoisonDepartment of Neurosurgery, Robert Wood Johnson Medical School, Rutgers University, Piscataway, NJ 08854, USA.
Jay M BaltzOttawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada.
Ottawa Hospital · CAOttawa Hospital Research InstituteRutgers, The State University of New Jersey · US

Funding

Glycine augmentation therapy for the treatment of epilepsyR01NS084920 · NINDS · LEGACY EMANUEL HOSPITAL AND HEALTH CENTER · PI SHEN, HAIYING · 2014 to 2018
$1.8M
CIHR PJT152991NINDS NIH HHS R01 NS084920
6 · The paper itself

Abstract

Early preimplantation mouse embryos are sensitive to increased osmolarity, which can block their development. To overcome this, they accumulate organic osmolytes to maintain cell volume. The main organic osmolyte used by early mouse embryos is glycine. Glycine is transported during the mature egg and 1-cell to 4-cell embryo stages by a transporter identified as GLYT1, encoded by the

Indexed as

Glycine Plasma Membrane Transport ProteinsOocytesAnimalsBlastocystFemaleGlycineMiceOsmotic PressureGlycineGlycine Plasma Membrane Transport ProteinsSlc6a9 protein, mousecell volumecumulusglycineGLYT1knockoutmouseoocyteosmolytepreimplantation embryotransport

Identifiers

PMID37887344
PMCPMC10604916
OpenAlexW4387843514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.